Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNY4 pseudogene 18 (RNY4P18) is one of several non-coding DNA sequences in the human genome that share high sequence similarity with the functional gene RNY4 (RNA, Ro60-associated Y4), a small non-coding RNA of the Y RNA family. Like other pseudogenes, RNY4P18 is the product of gene duplication or retrotransposition events and does not transcribe a functional RNA or protein. There is no scientific evidence that RNY4P18 has any independent biological function, acts as a receptor, enzyme, transporter, or drug target, or is involved in disease processes. Most literature on Y RNAs and their fragments in pathology—such as their upregulation as biomarkers in lymphoma, leukemia, and other malignancies—refers to the functional RNY4 gene or indistinguishable fragments, not to pseudogenes like RNY4P18[1][2][3][5]. Thus, RNY4P18 is not considered a therapeutic or diagnostic target, and its inclusion as a target entity is likely due to a misunderstanding or confusion with functional Y RNAs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNY4 pseudogene 18 (RNY4P18).